Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So how does it work then? PSTI will be out of money in Q1 2020 IF EVERYTHING goes without new issues.
The FIRST of the PLX trials won't even complete until the END of Q4, ie Vision 2020...
Anyone see an issue here? (the estimate includes draining the ATM)
WHERE O'WHERE will the rest of the money come from??!?
Remember, we were told 9 months ago, we had a burn rate that would get us through the 1st approval. Now there are 9 months there is NO funding for...
INDEPENDENCE is gone.
ps, NO mention of R18/DOD is beyond the pale and reprehensible. Not even a 'we are talking' anymore it seems. Anyone remember R18 was to be the 'big surprise' out of left field that is the game-changer in the short term? CRICKETS.
Big Pharma Is Going Crazy Over PLX-Immune IMO !
Yet another baseless claim of efficacy and safety in an indication not yet fully studied...
Funny, if you worked for the company (and its pretty obvious you do at some legal capacity) this claim would be criminal activity, punishable by fines and imprisonment depending on the damage.
When you do stuff like this, any benefit that you do provide with research becomes useless. You toy with the hopes of many ill people with reckless disregard, and void of feeling. You are sick and in serious need of a conscience.
PS, if Big Pharma is 'going carazy' over PLX-Immune, they must be doing the happy dance in their cubicles... Because 1 thing is for certain, they sure as hell are not buying ANY shares and nobody fears a takeover.
and... if this idiot twosome prices ANY of these indications at 70-80K they will have sold EVERYONE down the river. IF, IF, IF... the value of these products would be in the $250K-$500K per treatment if they are curative. There are already treatments that are well into the millions for a lifetime of chronic treatment. How much more for cures...
Anyone bothered to bring up the fact that their burn-rate accelerated by 9 months?
Just Words...Just Words...Notice the lack of creativity with this one. Verbatims without evidence. The more he talks, the less confidence investors have.
and we may all fart gold bars tonight by midnight.... probably more likely.
...and all this blah, blah, blah and the SP cannot even hold $.02 at $1.20 with DOUBLE the volume.
There is A LOT of wasted breath here, THAT I can tell you.
"I have the CURE in my pocket" and it is OBVIOUSLY still there, a little more smelly and moldy.
Has to be reported by psti though. They are not a third party...
Is not like standard Cogs but it must and Will Be reported IF and WHEN it happens, allo. Don't be silly. It hasn't happened yet.
Correction, It Was 400K !
Hey, close enough allo. With your math, you could be a Co-CEO somewhere. It would appear also that NO drug has been sold to initiate the 'EXPANDED ACCESS' trials unfortunately!
HMMMMM Edison values psti at $1.87. Seems in strong conflict to our resident toechartmongrel's latest tweets...
https://maya.tase.co.il/reports/details/1193780/2/0
"We have slightly adjusted our valuation to $212m or $1.87 per basic share from $212m or $1.92 per basic share driven by rolling forward our NPVs, partially offset by a lower cash position and a change to PRV sale timing expectations. The decrease in share price is due to a rise in share count. We continue to expect the company to require $50m in additional capital to reach profitability in 2020."
Also know as a devaluation, downgrade or whatever you want to call it other than a 'Strong Buy'.
I know its in the others, but not the last one. That was my point. Probably should file an update on the report since it was not correct.
Yes, BIG NEWS!!!
The news is we will have burned another $66,666.66 in the 24hrs since you post.
And everyday thereafter until the BIG NEWS announcement of a RS.
allo… why don't you cutnpaste it right here for all to see, from the last 10K.
Many laughs here allo…
No such thing mentioned in the past. It's new, explicitly NEW.
Translations:
'close support' = inspection for compliance
'repaying royalties' = fines for non-compliance
Oh, correction... It was 6 hours ago...
Obviously, NO, breaking news!
1/4 conference busts.
BIOEUROPE...
Funny, can't find PSTIs 'presentation' anywhere... After all they were 'invited to present' according to the pr...
http://www.rsc.org/events/detail/33358/bio-europe-conference-copenhagen-2018-24th-annual-partnering-conference
Does this mean all of the letters to shareholders touting 'partnership' efforts are lies and misrepresentations?!?!
Looks like one of the 3 had been reasigned... A strong sign they will soon bail on this company and board...
Now it's Astra Zenica... Next week it will be Walmart.
And BIOEUROPE?! Swiss miss?!
Just a big MISS...
Place this gently in your DD pipe...
The Company will also present at the BioEurope, Annual Vascular Interventional Advances and Cell and Gene Therapy Manufacturing conferences, all held in November
HAIFA, Israel, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.(PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company will be presenting at four conferences during November: at the BioEurope conference, which is being held November 5–7, 2018 in Copenhagen, at the 15th Annual Vascular Interventional Advances (VIVA) Conference, which is being held November 5-8 in Las Vegas, at the 2018 American Heart Association (AHA) Scientific Sessions, which are being held November 10-12 in Chicago and the Cell and Gene Therapy Manufacturing conference, which is being held November 14-15 in London.
Is that down from 33 institutions? More tutes selling this year than buying. 3-4% overall tute ownership, WELL below industry average.
DUMPED by UTHD, FELL LIKE A ROCKtober and this is starting to become another NONEVERNOVEMBER to forget all together!!
2 earth shattering conferences, predicted to 'launch this rocket' are done, and not a single drop of rocket fuel in any announcements... VIVA and AHA data 'invited' presentations a bust.
Pumps and Dumps from the chumps.
Where's the breaking news from AHA and VIVA in this NO!vember
Sorry, you lost this Bet... Go away now. You promised.
Any mustard gas updates allo? Wasn't even a mention at BARDA day....
And I don't mean your breath.
Yes, so is PSTI with their United Therapeutics 'PARTNERSHIP' picture with zami STILL here...
Just par for the course with this company...
Tick tock... Deadline from FDA fast approaching.
Fact is, if we don't get a positive opinion within 18 months from the FDA there are MUCH Bigger issues. They have to issue a decision either way. That's where the 'year of the shareholder' came from in the first place.......... Imho
Mikems, brilliant Metafores. Right now they would take a partnership with a millstone.
Yes exactly this was the definition of a United Therapeutics failure. They just couldn't deal with these amateurs and are now locked and loaded with cellularity! Just compared the two companies
check that you actually can't compare these two companies!
Number one reason there is NO Contract and no deal with BARDA. Simply NOT a viable option for IN-THEATRE use.
Been saying that for 2+ years. Thus the need for all in one device.
Look at the NON EVENT BARDA DAY FOLKS!!!!
UNTIL psti has the all in one, it's going Nowhere. Thus the need for TF deal...
Connect the dots, folks.... IMHO.
Vials and syringes won't cut it...
Allo, we are already conditionally approved by the FDA. WHAT'S THE HOLD UP FOR THE STOCKPILING ORDERS THAT YAKI IS WORKING ON?!?!?!
You make stuff up, allo. You don't know if there is a non complete. You are blowing smoke. Thanks for the laughs. !!
And so what's the hold up now?
We only needed the media and cell culture, not manufacturing, remember? We are fully integrated and "off the shelf" per allo.
Scary to see were are chasing now and not leading...
Hopester, was the death your clinging to here, a result of the study drug or the disease process?
It seems thou art asserting it is a safety issue with the drug and it is not safe.
Please clarify for us.
I really miss zzaatt.
"Gut" carries no weight with the Market.
YOU Hopester are one to talk... He who enters psti with their 'big toe' in the water to test... Nothing more than YOUR Gut and Toe.
You are LESS than disingenuous.
End of script.
Companies Making Progress!!
Webinar: WellSky – greater efficiency, safety for cell therapy labs
As the possibilities of cellular therapy continue to expand, you need a solution that can manage and document all the steps required for quality production so your lab can grow within a fast evolving, highly regulated industry. Learn how WellSky and Digi-Trax have teamed up to provide that solution. Join us for a free webinar on Nov 7, 9 AM GMT+10 (Nov 6, 5 PM US CDT). Register Now!
Arizona-based biotech startup BioLab Sciences announces patent for regenerative tissue therapy, MyOwn Skin™
SCOTTSDALE, Ariz., Oct. 24, 2018 — BioLab Sciences, an innovator in regenerative medicine technologies, announced its exclusively licensed technology for MyOwn Skin™, a painless, non-surgical procedure, which leverages a patient’s own skin to produce full-thickness skin grafts in 5-7 days.
Propagenix – Interview with the President and CEO, Brian Pollok, Ph.D.
Propagenix is a preclinical-stage platform technology company that is applying its unique technology to both internal and partnered cell therapy programs. The company is engaged in the development and commercialization of technology which originated from the laboratory of Dr. Richard Schlegel of Georgetown University. Headquartered in Rockville, Maryland, Progagenix was founded in 2014 by Brian Pollok, Ph.D.
Eppendorf presents first internally developed CO2 incubator
Hamburg, October 2018 — “Today’s cell culture requires more than technical solutions for optimized growth conditions and efficient contamination prevention,” says Eppendorf´s Business Manager for cell culture products Dr. Patrik Ferreira. “For several years, customers involved in Eppendorf´s development process have reported an increasing demand for devices that provide flexibility, support with increasing documentation demands and use natural resources sustainably.
Cell Care Therapeutics Raises $4.3 Million in Seed Funding
MONROVIA, Calif. — Cell Care Therapeutics, Inc., a biotechnology company whose mission is to advance stem-cell derived therapies in ophthalmology, announced the closing of a $4.3 million seed round investment from a syndicate of individual investors.
Sistemic & Cynata sign Global Service & License Agreement for the use of SistemPSCCheck™
Glasgow, UK; 22 October 2018 - Sistemic Ltd. has completed a Global Service and License Agreement for its SistemPSCCheck™ assay with the Australian stem cell and regenerative medicine company, Cynata Therapeutics. The agreement will see the use of the SistemPSCCheck™ assay for the assessment of residual pluripotent stem cells in Cynata’s current iPSC-derived MSC clinical candidate CYP-001, as well other planned iPSC-derived MSC products.
Forever Labs, Is It Worth $7,000 to Save Cells from Your Younger Self?
Forever Labs is one of the first companies worldwide to offer stem cell storage for adults. Interestingly, there is a prolific market for the storage of newborn tissues, including umbilical cord blood, umbilical tissue, and placental blood and tissue. However, storage for stem cells from adult tissues is extremely limited. Could it be worth $7,000 to store your stem cells before you (and they) get too old?
Exosome Companies | Tiny Exosomes, Enormous Potential
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. This article profiles 15 companies that have emerged as technology leaders within this rapidly expanding industry.
What Is Multiple Sclerosis? | FAQs
Multiple sclerosis (MS) is a complex and long-lasting disease that causes damage to your brain and nerves. Multiple sclerosis occurs when your immune system attacks myelin, a fatty material that shields your nerve fibers. Learn more about multiple sclerosis treatment and how stem cells may help in treating this condition.
Can Asthma Treatment Be Achieved Through Stem Cell Therapy?
Progress with regenerative medicine is supporting the development of a new type of asthma treatment that has the potential to reduce asthma attacks and repair lung damage. One in every 12 people suffer from asthma, making cellular solutions to this disease of critical importance.
Cell Therapy Manufacturing Survey – Selection Criteria for Choosing a CMO Partner (50% Off)
In this 21-page, 50+ respondent survey, cell therapy manufacturing executives reveal when and why they choose to partner with a contact manufacturing organization (CMO). It reveals the selection criteria that cell therapy executives use, as well as their perspectives on manufacturing capacity, geography, pure-play versus hybrid CMOs, and much more. For the next 48 hours, you can claim it for 50% off (only $97).
Global Induced Pluripotent Stem Cell Industry Report 2018-19 [Recently Released, October 2018]
Recent years have seen major advances in clinical applications, production and differentiation technologies, and biobanking of iPSCs. Interest in the therapeutic applications of iPS cells arises from their use in drug development and discovery, toxicology screening, disease modeling, and cell transplantation. Claim this 146-page report to access critical 2018-19 data that reveals market size, segments, trends, future growth projections by product category, and the competitive advantages of dominant market competitors, including CDI (a Fujifilm company), Ncardia, ReproCELL (Stemgent), Axol Bioscience, and others.
Magenta stem cell transplant drug seems to work, but is it safe?
Not only SAFE, but EFFECTIVE TOO!!!! GIDDY UP !
Will be available WAY ahead of PLX-IMMUNE.